news

Analysis finds COVID-19 infection may provide protective immunity

A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.

SARS-CoV-2 viral particle in crosshares with words 'target locked' above

A study of the immune response in more than 180 patients recovering from COVID-19 has indicated “that durable immunity against secondary COVID-19 disease is a possibility in most individuals”.

According to the authors of the paper, these patients’ immune memory to the virus – across all immune cell types studied – was measurable for up to 8 months after symptoms appeared. These findings help to answer the question of whether an initial infection with SARS-CoV-2 (the virus that causes COVID-19 disease) leads to long-lasting protective immunity against reinfection.

The authors performed the study because they believed studying the nature of the humoral (antibody) and cellular immune response (including B and T cells) to the virus over periods of six months after symptom onset could help ascertain the duration of protective immunity. The team analysed a total of 254 samples taken from 188 US patients who had recovered from COVID-19. The majority had had mild symptoms that did not require hospitalisation, though seven percent were hospitalised.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

Most subjects provided a blood sample at a single time point, between six days and eight months after symptoms took hold, though 43 samples were provided at 6 months or more following symptom onset. The samples were analysed for antibodies, B cells (which produce antibodies) and two types of T cells (which kill cells that are infected). The found:

  • Antibodies, including those targeting the SARS-CoV-2 Spike (S) protein components, were relatively stable over six months – only exhibited modest declines at six to eight months after symptom onset.
  • S protein-specific memory B cells were found to be more abundant six months after the onset of symptoms than at one month after.
  • However, SARS-CoV-2-specific CD4+T cells and CD8+ T cells declined more rapidly, with a half-life of three to five months.

While they caution that “direct conclusions about protective immunity cannot be made on the basis of [their findings] because mechanisms of protective immunity against SARS-CoV-2 or COVID-19 are not defined in humans,” they suggested that a “reasonable” interpretation could be that resting immune memory compartments potentially contribute “in meaningful ways to protective immunity against pneumonia or severe secondary COVID-19”.

The study was published in Science.